Olema Other Current Liab vs Non Currrent Assets Other Analysis
| OLMA Stock | USD 12.72 0.32 2.58% |
Olema Pharmaceuticals financial indicator trend analysis is much more than just breaking down Olema Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Olema Pharmaceuticals is a good investment. Please check the relationship between Olema Pharmaceuticals Other Current Liab and its Non Currrent Assets Other accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.
Other Current Liab vs Non Currrent Assets Other
Other Current Liab vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Olema Pharmaceuticals Other Current Liab account and Non Currrent Assets Other. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Olema Pharmaceuticals' Other Current Liab and Non Currrent Assets Other is 0.88. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Olema Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Olema Pharmaceuticals' Other Current Liab and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Olema Pharmaceuticals are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Other Current Liab i.e., Olema Pharmaceuticals' Other Current Liab and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.88 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Other Current Liab
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Olema Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Olema Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 130.3 M, whereas Selling General Administrative is forecasted to decline to about 13.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.7M | 357K | 377K | 445.9K | Interest Income | 442K | 2.2M | 5.7M | 6.0M |
Olema Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Olema Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Olema Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 132K | 342.7M | 295.9M | 215.6M | 276.9M | 208.0M | |
| Other Current Liab | 443K | 3.9M | 378K | 15.2M | 17.9M | 18.8M | |
| Total Current Liabilities | 1.4M | 4.6M | 9.0M | 16.5M | 21.6M | 22.7M | |
| Total Stockholder Equity | (10.6M) | 338.1M | 284.6M | 197.5M | 253.9M | 193.8M | |
| Net Tangible Assets | (10.6M) | 338.1M | 284.6M | 197.5M | 227.2M | 176.7M | |
| Net Debt | (68K) | (338.5M) | (284.0M) | (21.1M) | (66.1M) | (69.4M) | |
| Retained Earnings | (10.8M) | (33.1M) | (104.2M) | (209.0M) | (305.6M) | (290.4M) | |
| Accounts Payable | 935K | 719K | 23K | 374K | 2.7M | 2.8M | |
| Cash | 68K | 338.5M | 287.3M | 23.7M | 68.5M | 132.2M | |
| Cash And Short Term Investments | 68K | 338.5M | 287.3M | 204.4M | 261.8M | 200.8M | |
| Common Stock Shares Outstanding | 40.2M | 39.3M | 39.5M | 40.0M | 45.2M | 40.0M | |
| Liabilities And Stockholders Equity | 132K | 342.7M | 295.9M | 215.6M | 276.9M | 208.0M | |
| Other Current Assets | 35K | 149K | 223K | 4.5M | 4.0M | 4.2M | |
| Other Stockholder Equity | 168K | 371.2M | 388.9M | 408.3M | 559.2M | 316.8M | |
| Total Liab | 10.7M | 4.6M | 11.4M | 18.1M | 23.1M | 14.2M | |
| Net Invested Capital | (10.6M) | 338.1M | 284.6M | 197.5M | 253.9M | 193.8M | |
| Total Current Assets | 103K | 342.1M | 287.3M | 208.9M | 266.5M | 203.2M | |
| Accumulated Other Comprehensive Income | (9.3M) | (342.7M) | (149K) | (1.8M) | 347K | 364.4K | |
| Net Working Capital | (1.3M) | 337.6M | 281.7M | 192.4M | 244.9M | 194.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Return On Assets (0.35) | Return On Equity (0.56) |
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.